Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

$40m-$99.9m

Ribo Life Science realises series C2 round
SAIC Motor fund Hengxu Investment and a Sinopharm-backed joint venture were among the investors in a $66.3m round for the RNA drug developer.
Pandion packs in $80m
Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.
Aspen Neuroscience ascends with $70m
The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.
Affinia affirms $60m series A
Lonza participated in the gene therapy developer's series A round alongside Partners Innovation Fund, having also licensed technology to the startup.
Olive collects $51m
General Catalyst led a $51m round for the Ascension-backed healthcare automation technology developer, which has now received $119m in total.
Daojiale houses funding from 58.com
58.com and its 58 Aifang subsidiary invested $70.5m and will help the online real estate marketplace expand its services and grow throughout southwestern China.
NextVPU executes series B round
Cethik-backed artificial intelligence chipmaker NextVPU has received $42.3m from unnamed investors to scale its research and development activities.
Kyash gets series C payment
The corporate-backed mobile banking services provider collected $43.6m in a round co-led by Goodwater Capital and Greenspring Associates.

Other News

Huilianyi hauls in series C-plus funding
SoftBank China Venture Capital returned for a $42.3m round that will support the international growth of Huilianyi's expenses management software.
Dremio drops $70m series C funding details
The data management software provider has now secured a total of $115m, Cisco Investments returning to back its latest round.
Nature's Fynd unearths $80m
The edible protein developer has rebranded from Sustainable Bioproducts and received series B funding from investors including existing backers Danone and Archer Daniels Midland.
Abbisko absorbs $70m
Lilly Asia Ventures, an investor in the cancer drug developer since its series A round, returned to back a series C that doubled its overall funding to $140m.
Design Therapeutics draws up $45m series A
SR One led a round disclosed by the genetic medicine developer, a spinout of University of Wisconsin-Madison, as it emerged from stealth.
Sigilon signs off on series B funding
Eli Lilly took part in an $80.3m round that pushed chronic illness drug developer Sigilon Therapeutics' overall funding to nearly $200m.

Editor's Picks

No posts to show.

test reg

Login